Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Although revenue was affected by drug price revisions and other factors, revenue increased 0.3% year on year as a result of efforts to expand new and core products. Core operating profit increased 9.3% year on year due mainly to higher gross profit, while operating profit increased 7.2%. Income tax expense decreased by ¥500 million from the same period of the previous year, and profit for the quarter attributable to owners of the parent increased 22.4%.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥68,957 million (YoY +0.3%) |
| Operating profit | ¥8,116 million (YoY +7.2%) |
| Ordinary income | ¥8,335 million |
| Profit attributable to owners of the parent | ¥7,194 million (YoY +22.4%) |
| Net income per share | ¥22.38 |
| Equity ratio | End of the current fiscal period 72.2 / End of previous period 70.2 |
| Total assets | ¥415,849 million |
| Net assets | ¥299,269 million |
| Cash flows from operating activities | ¥5,258 million |
| Cash flows from investing activities | ¥-900 million |
| Cash flows from financing activities | ¥-7,887 million |
| Cash and cash equivalents at end of period | ¥78,258 million |
| Full-year earnings forecast | Net Sales ¥311,000 million (YoY +6.6%) / Operating profit ¥49,500 million (YoY +3.6%) / Ordinary income Not disclosed / Net income ¥40,000 million (YoY +7.0%) |
| Annual Dividend Forecast | ¥38 → ¥42（+10.5%） |
| Regional sales | Region Japan / Net Sales 296 Hundreds of millions of yen / yoy_pct -19.3, Region China / Net Sales 75 Hundreds of millions of yen / yoy_pct 19.5, Region Asia (excluding China) / Net Sales 95 Hundreds of millions of yen / yoy_pct 39.4, Region EMEA / Net Sales 219 Hundreds of millions of yen / yoy_pct 17.7 |
| Depreciation and amortization | 17 Hundreds of millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 322,290,154 shares |
| Treasury Shares at Period-End | 1,099,863 shares |
| Factors Behind Changes in Business Performance | Although revenue was affected by drug price revisions and other factors, revenue increased 0.3% year on year as a result of efforts to expand new and core products. Core operating profit increased 9.3% year on year due mainly to higher gross profit, while operating profit increased 7.2%. Income tax expense decreased by ¥500 million from the same period of the previous year, and profit for the quarter attributable to owners of the parent increased 22.4%. |
Items this document does not state (9)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Although revenue was affected by drug price revisions and other factors, it increased as a result of efforts to expand new and core products. Core operating profit increased due mainly to higher gross profit, while profit for the quarter attributable to owners of the parent also benefited from lower income tax expense.